ARTICLE | Company News
Scripps Research Institute, T23 deal
July 14, 2014 7:00 AM UTC
T23 received exclusive, worldwide rights to develop and commercialize Scripps’ CD22 sialic acid binding Ig-like lectin (SIGLEC) oncoimmunological platform. The license covers complex formulations co...